Immune cells lacking Y chromosome show dysregulation of autosomal gene expression. by Dumanski, Jan P et al.
Vol.:(0123456789) 
Cellular and Molecular Life Sciences 
https://doi.org/10.1007/s00018-021-03822-w
ORIGINAL ARTICLE
Immune cells lacking Y chromosome show dysregulation of autosomal 
gene expression
Jan P. Dumanski1,2  · Jonatan Halvardson1 · Hanna Davies1 · Edyta Rychlicka‑Buniowska3 · Jonas Mattisson1 · 
Behrooz Torabi Moghadam1 · Noemi Nagy4 · Kazimierz Węglarczyk5 · Karolina Bukowska‑Strakova5 · 
Marcus Danielsson1 · Paweł Olszewski3 · Arkadiusz Piotrowski2 · Erin Oerton6 · Aleksandra Ambicka7 · 
Marcin Przewoźnik7 · Łukasz Bełch8 · Tomasz Grodzicki9 · Piotr L. Chłosta8 · Stefan Imreh10 · Vilmantas Giedraitis11 · 
Lena Kilander11 · Jessica Nordlund12 · Adam Ameur1 · Ulf Gyllensten1 · Åsa Johansson1 · Alicja Józkowicz13 · 
Maciej Siedlar5 · Alicja Klich‑Rączka9 · Janusz Jaszczyński14 · Stefan Enroth1 · Jarosław Baran5 · Martin Ingelsson11 · 
John R. B. Perry6 · Janusz Ryś7 · Lars A. Forsberg1,15 
Received: 19 October 2020 / Revised: 1 March 2021 / Accepted: 25 March 2021 
© The Author(s) 2021
Abstract
Epidemiological investigations show that mosaic loss of chromosome Y (LOY) in leukocytes is associated with earlier mor-
tality and morbidity from many diseases in men. LOY is the most common acquired mutation and is associated with aberrant 
clonal expansion of cells, yet it remains unclear whether this mosaicism exerts a direct physiological effect. We studied DNA 
and RNA from leukocytes in sorted- and single-cells in vivo and in vitro. DNA analyses of sorted cells showed that men 
diagnosed with Alzheimer’s disease was primarily affected with LOY in NK cells whereas prostate cancer patients more 
frequently displayed LOY in CD4 + T cells and granulocytes. Moreover, bulk and single-cell RNA sequencing in leukocytes 
allowed scoring of LOY from mRNA data and confirmed considerable variation in the rate of LOY across individuals and 
cell types. LOY-associated transcriptional effect (LATE) was observed in ~ 500 autosomal genes showing dysregulation 
in leukocytes with LOY. The fraction of LATE genes within specific cell types was substantially larger than the fraction 
of LATE genes shared between different subsets of leukocytes, suggesting that LOY might have pleiotropic effects. LATE 
genes are involved in immune functions but also encode proteins with roles in other diverse biological processes. Our find-
ings highlight a surprisingly broad role for chromosome Y, challenging the view of it as a “genetic wasteland”, and support 
the hypothesis that altered immune function in leukocytes could be a mechanism linking LOY to increased risk for disease.
Keywords LOY · Mosaic loss of chromosome Y · Differential gene expression · LATE · LOY-associated transcriptional 
effects
Introduction
For over 50 years it has been noted that chromosome Y is 
frequently lost in the leukocytes of aging men [1, 2] rep-
resenting the most commonly observed form of clonal 
mosaicism. Our recent work demonstrated that one in five 
men in the UK Biobank study have detectable LOY in blood 
[3, 4] reaching a prevalence of 57% in 93-year-old men [5]. 
Furthermore, LOY is considerably more common in periph-
eral blood leukocytes vs. other tissues [5, 6]. These obser-
vations have been accompanied by epidemiological stud-
ies linking LOY in blood to numerous disease outcomes, 
including all-cause mortality, Alzheimer’s disease, various 
forms of cancer, autoimmune conditions, age-related macu-
lar degeneration, cardiovascular disease, type 2 diabetes, and 
obesity [6–15]. Associations between LOY and blood cell 
counts have also been reported; platelet and red blood cell 
numbers are positively and negatively associated with LOY, 
respectively [16, 17].
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Recent large-scale population studies have highlighted 
a heritable component to LOY and begun identifying indi-
vidual genetic determinants. The largest to date, studying 
205,011 men in UK Biobank, identified 156 genetic loci 
associated with LOY, which were preferentially found near 
genes involved in cell-cycle regulation, cancer susceptibility, 
somatic drivers of tumor growth, and cancer therapy targets 
[4]. The emerging picture is that LOY is in part determined 
by genetic predisposition to deficiencies in DNA damage 
response—either through genetic effects that promote chro-
mosome mis-segregation or failure in the molecular machin-
ery to detect and appropriately deal with this damage. The 
remaining part might be due to other risk factors, e.g., smok-
ing and environmental hazards [18–20].
There are two main, not mutually exclusive hypotheses 
that could explain the link between LOY in blood and risk 
for disease—either loss of a Y chromosome in leukocytes 
exerts a direct physiological effect, and/or LOY in leu-
kocytes is a barometer of broader genomic instability in 
other cell types. Evidence for the latter emerged with the 
observation that genetic susceptibility to LOY influences 
non-hematological health outcomes in women (who are 
XX, hence eliminating a direct Y effect). This observation 
does not, however, preclude a direct effect of LOY that may 
explain some of the noted disease associations. Indeed, we 
recently reported that expression of TCL1A was dysregulated 
in CD19 + B-lymphocytes missing the Y chromosome, pro-
viding a proof-of-concept that LOY may not be functionally 
neutral in these cells [4]. The current study substantially 
expands this observation, demonstrating that LOY is asso-
ciated with dysregulation of autosomal gene expression in 
leukocytes. Furthermore, the biological nature of these dys-
regulated genes supports the hypothesis that altered immune 




Blood samples were collected from 408 male subjects in 
Uppsala, Sweden, and in Kraków, Poland. In Uppsala, sam-
ples from ULSAM, Alzheimer’s disease cohort (UAD), and 
controls (M) were collected during January 2015 to May 
2018, at the Geriatric/Memory Clinic, Uppsala Academic 
Hospital. In Kraków, samples from prostate cancer patients 
(KP) were collected from March 2015 to May 2018 at the 
Centre of Oncology, Kraków Branch and the Department 
and Clinic of Urology of the Jagiellonian University. Alz-
heimer’s disease (KAD) patients were collected from Janu-
ary 2017 to May 2018 at the Clinic of Internal Diseases 
and Gerontology of the Jagiellonian University in Kraków. 
Control samples (M) were collected from December 2015 to 
May 2018 from the general population of Kraków and Upp-
sala. The criteria for recruitment of prostate cancer patients 
was advanced stage prostate cancer, i.e., Gleason grade 7 or 
higher. The prostate cancer patients were recruited before 
treatment, or during the first stage of treatment. As for Alz-
heimer’s disease, patients with ongoing clinically and radio-
logically confirmed diagnosis were recruited. The clinical 
stage for recruited Alzheimer’s patients was intermediate or 
severely advanced disease. For the purpose of LOY analysis 
in sorted leukocyte subsets (Fig. 3), we used 107 prostate 
cancer patients, 121 Alzheimer’s disease patients, and 156 
age-matched controls.
Preparation and sorting of blood cells with FACS
We implemented two strategies for preparation of blood cells 
for sorting.
Isolation and labeling of peripheral blood mononuclear 
cells (PBMCs) for sorting of T‑ and B‑lymphocytes as well 
as NK cells
16 ml of blood was collected into BD Vacutainer® CPT™ 
Mononuclear Cell Preparation Tubes (BD). PBMCs were 
stained with 20 µl of BD Multitest™ 6-color TBNK reagent 
(BD) and incubated for 20 min. at 4 °C. After incubation, 
PBMCs were washed with PBS and cell pellets were resus-
pended in 1 ml of PBS containing 3 mM EDTA. PBMCs 
were filtered through 40 µm cell strainer to obtain real single 
cell suspensions by removing cell aggregates.
Isolation and labeling of white blood cells (WBCs) 
for sorting of granulocytes, monocytes, and B‑lymphocytes
16 ml of blood was collected into BD Vacutainer® K2 
EDTA tubes (BD). Red blood cells were lysed using 1 × BD 
Pharm Lyse™ lysing solution (BD) added to blood samples 
up to 50 ml. Samples were incubated at room temperature 
for 10 min. The lysing step was repeated and cells were then 
washed with PBS. Isolated white blood cells (WBCs) were 
stained with following antibodies: 5 µl of PE-labeled CD14, 
clone MφP9 (BD), and 20 µl of APC-labeled CD19, clone 
HIB19 (BD) and incubated for 20 min. at 4 °C. After incu-
bation, WBCs were washed with PBS and cell pellets were 
resuspended in 2 ml of PBS containing 3 mM EDTA.
Sorting of target cell populations with FACS
The target populations were isolated using FACS Aria III 
(Becton Dickinson), FACS Aria II (Becton Dickinson), and 
MoFlo (Beckman Coulter). Data were acquired and ana-
lyzed using BD FACSDiva™ Software (Becton Dickinson) 
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with FACS Aria III and FACS Aria II or Summit™ Soft-
ware System (Cytomation) with MoFlo. Live cells were 
sorted based on their FSC and SSC. CD4 + T cells were 
defined as CD45 + CD3 + CD8 − CD4 + ; CD8 + T cells 
were defined as CD45 + CD3 + CD4 − CD8 + ; B cells 
were defined as CD45 + CD3 − CD19 + ; NK cells were 
defined as CD45 + CD3 − CD4 − CD16 + CD56 + ; mono-
cytes were defined based on their size and as CD14 + ; 
granulocytes were defined based on their size and granu-
larity, and additional B cells were defined based on their 
size and CD19 + . Cells were sorted to achieve the purity 
of above 96%. At least 200,000 cells of each type were 
sorted. After sorting, cells were centrifuged and 1 ml of 
RNAProtect (Qiagen) was added to cell pellets.
Establishment of lymphoblastoid cell lines (LCLs)
The LCLs were generated using Epstein–Barr virus (EBV) 
transformation of lymphocytes collected from six male 
donors with previously established LOY in whole blood 
[5]. These control subjects were derived from the Uppsala 
Longitudinal Study of Adult Men (ULSAM) cohort and 
were free from cancer or Alzheimer’s disease diagnosis 
at the age of 91–94 years. Peripheral blood mononuclear 
cells (PBMC) were isolated from blood by Ficoll-Paque 
gradient separation. PBMC were infected with EBV by 
incubating them with supernatant of the virus producing 
B95-8 line for 90 min at 37 °C. Thereafter, the cells were 
washed and resuspended in complete RPMI-1640 medium 
(supplemented with 10% heat inactivated FCS, penicil-
lin, and streptomycin). 1 µg/ml Cyclosporine A was added 
to the cultures to inhibit T cell expansion and function. 
After 3 weeks of culturing, transformed cells were plated 
into microtitre plates at a 1 cell/well density. In each well, 
gamma-irradiated human fibroblasts (5000 rad) served as 
feeder cells.
LOY analyses using DNA from sorted cells and LCLs
DNA extraction
DNA was extracted using an in-house protocol with lysis 
buffer containing 10 mM EDTA, 10 mM Tris–HCL (pH 
7.9), 50 mM NaCl, and 1% N-Lauroylsarcosine sodium 
salt (Sigma) with 10 mg/ml proteinase K (Sigma) and 
incubated for 2 h in 50 °C. The DNA was then precipitated 
and resuspended in water. DNA was extracted from blood 
using QIAmp DNA Blood Midi kit (Qiagen). The con-
centration was measured using Quant-iT™ PicoGreen® 
dsDNA Assay Kit (Thermo Fisher Scientific).
Genotyping and LOY analysis using SNP‑arrays
All genotyping experiments were performed following the 
manufacturer’s instructions at the Science for Life tech-
nology platform SNP&SEQ at Uppsala University, Swe-
den. DNA extracted from the FACS sorted populations 
was genotyped using three different versions of Illumina 
SNP-arrays (InfiniumCoreExome-24v1-1, InfiniumOm-
niExpressExome-8v1-3 and InfiniumQCArray-24v1). 
All included experiments passed strict quality control at 
the genotyping facility and additional quality assessment 
as described previously [7]. The Log R Ratio (LRR) is a 
commonly used metric to determine copy number states 
from SNP-array data. The “R” represents probe intensity 
estimates and the LRR is the logged ratio of the observed 
probe intensity to the expected intensity. Thus, deviations 
from zero in the LRR values of probes located in a specific 
genomic region is indicative of copy number change. For 
the estimation of LOY mosaicism in the present study, 
we calculated the median of the LRR values (i.e., the 
mLRRY) of the SNP-array probes located in the male-
specific region of chromosome Y (MSY) as described pre-
viously [7]. This generated a continuous estimate of LOY 
for each sample. Thus, mLRRY estimates around zero 
indicate a normal chromosome Y state, whereas samples 
with higher levels of LOY mosaicism show more negative 
mLRRY values. To correct for genotyping batch effects, 
we calculated the local regression median (LRM) in each 
batch and the mLRRY value for each subject was, thereaf-
ter, corrected by the batch-specific LRM. The percentage 
of normal cells without LOY in each sample was estimated 
using a formula described previously, i.e., using the for-
mula: LOY(%) = 100*(22*mLRRY ) [21].
Experiments and LOY analysis using digital droplet PCR 
(ddPCR)
Additional quantification of the level of LOY for validation 
was performed using previously described procedure [21]. 
Briefly, extracted DNA was digested for 15 min with Hin-
dIII enzyme (Thermo Fischer) in 37 °C. After this, 50 ng of 
DNA was added together with PCR primers and probes tar-
geting a known difference between the AMELX and AMELY 
gene assay C_990000001_10 (Thermo Fisher). Droplets 
were then generated using an automated droplet generator 
(Bio-Rad) and amplified using PCR. Droplets fluorescence 
intensity in two channels FAM and VIC was measured using 
the Bio-Rad’s QX200 Droplet Reader. The data were ana-
lyzed in Bio-Rad’s software QuantaSoft (version 1.7.4.0917) 
as described elsewhere [21]. The LOY quantification was 
performed by calculating the ratio between the amounts of 
AMELY and AMELX in each sample.
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Experiments using bulk RNA from sorted cells 
and LCLs
RNA extraction
RNA was extracted from cell pellets using RiboPure™ RNA 
Purification Kit (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Possible DNA contamination 
was removed using TURBO DNA-free™ Kit (Thermo 
Fisher Scientific). The RNA was then concentrated using 
GeneJET RNA Cleanup and Concentration Micro Kit 
(Thermo Fisher Scientific). RNA quality was measured with 
RNA Pico Chip (Agilent Technologies) and analyzed using 
Agilent 2100 Bioanalyzer (Agilent Technologies).
Bulk RNA sequencing (RNAseq)
Bulk RNA sequencing was performed by the Science for Life 
technology platform at Uppsala Genome Centre (Uppsala 
University, Sweden). For each sample, an average of 10 ng 
of RNA (1–100 ng) from the FACS sorted samples was used. 
Library preparation was performed using the Ion Ampliseq 
Human Gene Expression kit (Thermo Fisher Man0010742). 
Libraries were loaded onto Ion 550 chips following recom-
mendations from the manufacturer (MAN0017275) and 
sequenced using an Ion S5 XL instrument.
Analysis pipeline of bulk RNAseq data from sorted cells
For each of the FACS sorted samples analyzed using the 
Ion Ampliseq Human Gene Expression kit, raw read-
counts were read into the R (v3.5.3) software, and one 
matrix of read-counts was created per cell type. Outli-
ers and low quality expression data were identified within 
each cell type using principal component plots. Only 
among the monocyte samples, eight outliers were identi-
fied and removed. Estimation of the level of LOY in each 
sample in the RNAseq data was performed by a variance-
stabilizing transformation applied in the R library DESeq2 
(v1.22.2) [22] using the varianceStabilizingTransforma-
tion function, to the count matrix to make the expression 
more coherent. A mean expression was then calculated for 
all genes on the autosomal chromosomes, and compared 
to the mean expression of the MSY genes, generating a 
fraction of expression for the Y chromosome. The calcu-
lated fractions were rescaled to fit between 0 and 100. This 
was done per cell type, to avoid cell type specific biases 
in expression levels. Next, normally expressed genes in 
the sorted cell fractions were identified by the analysis 
of samples without LOY. In these, genes with at least ten 
sequencing reads in more than 75% of the samples with-
out LOY were considered normally expressed. To inves-
tigate associations between LOY and expression level of 
chromosome Y genes, we applied a non-linear least square 
model, using nls() function in R, on average expression of 
all selected MSY and PAR genes and percentage of LOY 
in samples of each cell type. For each cell type, the expres-
sion level of each sample was divided by the maximum 
expression level among all samples to generate estimates 
between 0 and 1. We estimated the LOY-associated tran-
scriptional effects (LATE) in the RNAseq data as follows. 
DESeq2 (v1.22.2) [22] was used to identify genes with 
differential expression in the leukocytes derived from each 
patient. As LOY is a continuous trait, the percentage of 
LOY estimated from SNP-arrays for each sample was used 
for statistical testing. To decrease the impact of read-count 
outliers the fraction of LOY was binned using 20% inter-
vals between < 20% and 80% < and these bins were used as 
a continuous input variable for DESeq2. We investigated 
the effect on gene expression from known and potentially 
confounding variables (e.g., age, clinical characteristics, 
collection center, and sequencing batch) and determined 
to include sequencing batch as a covariate in the analysis 
of differentially expressed genes. Independent filtering of 
genes in DESeq2 was done using the default value of 0.1 
for the alpha parameter, which was also used as a cutoff 
for the DESeq2 adjusted p values.
Analysis pipeline of bulk RNAseq data from LCLs
We used R (version 3.5.2) and the edgeR (version 3.24.3) 
library to compare the expression between LCLs with the 
Y chromosome and LCLs with LOY in two steps. As all 
the clones with LOY were derived from the same indi-
vidual (this individual also gave rise to one non-LOY 
clone), we designed the analysis to remove inter- and 
intra-individual differential expression effects. As step 
one, to identify the intra-individual differences, we tar-
geted the differential expression genes among the normal 
LCLs by comparing each non-LOY individual’s clones 
with all other non-LOY clones. The union of all differen-
tially expressed genes resulted out of each comparison was 
gathered into List1 (Supplementary Fig. 5). This gave us a 
set of genes that are differentially expressed between sub-
jects but not due to LOY status. As step two, we targeted 
the differentially expressed genes regarding LOY status 
in two steps: first by comparing the non-LOY versus LOY 
clones derived from the same individual; second by com-
paring all non-LOY versus LOY clones and the overlap of 
the results of steps one and two was gathered into List2. 
The final list of LATE genes was generated by comparing 
List2 and List1 and extracting the differentially expressed 
genes that exist in List2 but not in List1, to remove the 
intra-individual differentially expressed genes from the 
LATE genes.
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Experiments using RNA from single cells
Sample preparation
Blood was collected using BD Vacutainer CPT tubes (BD 
Biosciences). PBMCs were isolated using density gradi-
ent centrifugation and resuspended in 0.04% BSA 1X PBS 
solution. Concentrations were measured using an EVE cell 
counter (NanoEnTek, Seoul) and cells were diluted to  106 
cells/ml.
Single cell RNA sequencing (scRNAseq)
The collected PBMCs were loaded on a 10X Genomics 
Chromium Single Cell 3′ Chip v2 for sequence library gen-
eration using protocol CG00052 (10X Genomics) using a 
3′-end protocol. The single cell libraries were sequenced on 
Illumina HiSeq2500 and NovaSeq instruments The single 
cell library preparation and sequencing were performed at 
the Science for Life technology platform SNP&SEQ, Upp-
sala University, Sweden.
Analysis pipeline of single cell scRNAseq data
Sequence reads were mapped to the hg19 version of the 
human genome using CellRanger v2 (10X Genomics) and 
recommended settings. The produced raw reads matrices 
were analyzed using R (v3.4) and the R library Seurat (v2.2) 
[23]. For each sample, the read-count matrix was used to 
create a Seurat object in R. After this, all data were log nor-
malized and variable genes were identified using standard 
settings from the Seurat manual. Data were then scaled and 
the principal components were calculated. Then, the num-
ber of informative principle components for each sample 
was identified using an elbow plot and cells were then clus-
tered using the findclusters Seurat function and informative 
principle components. A tSNE plot was produced with the 
resulting clusters of the nearest neighbor clustering indi-
cated by the color of each cell in the tSNE plot, to confirm 
consistency. An in-house R script was then used to calculate 
the level of expression of cell marker genes in each cluster 
and cell types was assigned using the strongest expression 
signal. These results were then manually inspected using 
heatmaps to confirm the automated cell-type assignment. 
Following this step, all individuals were merged together 
creating one object for each studied cell type (monocytes, 
NK cells, T- and B- lymphocytes). The procedure outlined 
above was repeated for the merged data sets and the cells 
were filtered only keeping cells with at least 800 expressed 
genes but no more than 2000 expressed genes. This was done 
both to remove experiments where two cells were sequenced 
together, and to remove cells with a generally low expression 
of genes, where the LOY estimate may be erroneous. Cells 
with more than 5% mitochondrial RNA were also excluded, 
to remove possibly apoptotic and damaged cells from the 
analysis. To determine the LOY status in each single cell 
the number of reads mapping to autosomal genes and genes 
located in the male-specific region of chromosome Y (MSY) 
was counted. Each sequenced cell with expression of auto-
somal genes, but without any transcripts from genes located 
in the MSY was considered as a LOY cell as described else-
where [4]. To calculate the percentage of LOY in each sam-
ple and cell types, the fraction of cells having LOY was 
calculated for each specific cell type. Normally expressed 
genes were defined by the expression in at least 10% of 
single cells without LOY. After establishing the normally 
expressed genes in each cell type in the scRNAseq data, we 
further filtered the cells to include only cells having more 
than 2500 UMIs. This was done to remove possible false 
positive LOY cells, and only keep cells where a robust and 
high number of UMIs was found. We then identified genes 
showing differential expression (i.e., LATE genes) in the 
single cells dataset using the Seurat FindMarkers function. 
We used this function to test differences in gene expression 
in cells with and without LOY using the built-in negative 
binomial test.
Co‑expression analysis using single cell RNA dataset
We investigated if changes in expression as an effect of LOY 
would be larger in autosomal genes that are normally co-
expressed with MSY genes, compared with genes that are 
not co-expressed with MSY genes. We first identified six 
MSY genes that showed expression in normal leukocytes 
(i.e., without LOY) in the single cell data set (i.e., RPS4Y1, 
ZFY, USP9Y, DDX3Y, KDM5D, and EIF1AY). Next we 
identified the degree of co-expression between these six 
MSY genes and autosomal genes using the default settings 
in the SEEK database (http:// seek. princ eton. edu/). The 
applied algorithm identifies genes showing similar expres-
sion patterns across human samples in a large number of 
databases containing gene expression data from numerous 
sources [24]. From the generated list, we selected the top 
300 autosomal genes showing the most co-expression with 
the MSY genes and calculated the fold change of the changes 
in expression of these 300 genes in single cells with LOY 
compared with normal cells without LOY. Additionally, 
we calculated the equivalent fold changes for autosomal 
genes not showing co-expression with MSY genes. Follow-
ing this, the fold changes for the co-expressed and the not 
co-expressed sets of autosomal genes was used to produce 
plots, and a Wilcoxon rank sum test was used to test for dif-
ferences. Similar analyses were also performed separately 
within monocytes, NK cells, T- and B-lymphocytes, in 
which 142, 116, 95, and 122 co-expressed autosomal genes 
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as well as 3677, 3230, 2752, and 3075 autosomal control 
genes without co-expression were identified, respectively.
Functional annotation of chromosome Y genes
For annotation of known functions of chromosome Y genes 
summarized in Supplementary Fig. 1, a list of all genes 
located on the Y chromosome together with associated GO 
categories was downloaded from Ensembl (v. 95) using the 
R library bioMart (v2.38). The list was filtered for protein 
coding genes and annotated as either positioned in the male-
specific part of the Y chromosome (MSY) or in the pseudo-
autosomal regions (PAR). The GO categories for each gene 
were inspected manually and genes were assigned into four 
different categories: “Transcription, translation epigenetic, 
and PTM functions”, “Cell differentiation, migration prolif-
eration, and apoptosis”, “Sex determination, fertility, and 
other functions”, and “Immune response and immune cell 
signaling”.
Non‑random distribution of LATE genes
Over-representation of known biological connections 
between genes was calculated using the STRING web tool 
[25]. To evaluate the genomic clustering of LATE genes we 
plotted the largest differential expression (Supplementary 
Table 1) of each of the 489 autosomal LATE genes using a 
modified version of the plotManhattan function from the R 
package qqman [26] with chromosome lengths from https:// 
www. ncbi. nlm. nih. gov/ grc/ human/ data (assembly GRCh37).
Enrichment testing of LOY GWAS variants
To test the hypothesis that LATE genes might be preferen-
tially located near LOY-associated variants highlighted by 
GWAS [4] we performed gene set enrichment analysis using 
MAGENTA [27]. This was performed with the full GWAS 
summary statistic data using the recommended default run-
ning parameters of MAGENTA.
Gene set enrichment analyses
The 489 autosomal LATE genes were compared to the back-
ground of 11,884 tested genes. Gene symbols were mapped 
to Entrez Gene IDs using the org.Hs.eg.db Bioconductor 
package [28] resulting in 460 and 10,989 identifiers, respec-
tively. Enrichment of LATE gene Entrez IDs in GO terms 
was obtained as a DAVID Functional Annotation Chart of 
GO FAT terms via RDAVIDWebService [29]. Enrichment in 
Reactome pathways and the GO biological process complete 
set were additionally performed using the PANTHER [30] 
overrepresentation test, using Fisher’s exact test statistic.
Other statistical analyses
Statistical analyses such as logistic regression, linear regres-
sion, Fisher exact test, Kolmogorov–Smirnov test, and Wil-
coxon rank sum test were performed using R version 3.3.1 
(http:// www. rproj ect. org/), using two-sided tests and α-levels 
at 0.05 and default parameters, unless otherwise specified. 
When appropriate, correction of p values for multiple testing 
was applied. To define the LATE genes, we applied three 
stringency levels. The first was based on standard p value 
at α-level 0.05 and the second was a more stringent p value 
correcting for multiple testing (FDR < 0.1) using Benjamini 
and Hochberg (BH) correction. Furthermore, an additional 
criterion was applied to identify only the highly expressed 
LATE genes, i.e., using threshold of at least an average of 
100 reads per gene in RNAseq data.
Results
To investigate the functional consequences of LOY, we 
studied changes in gene expression associated with LOY 
in vivo and in vitro (see “Materials and methods”). The 
single-cell transcriptome analysis (scRNAseq) of peripheral 
blood mononuclear cells (PBMCs) collected from 29 men 
(median age 80 years, range 64–94 years) generated a pooled 
dataset encompassing 73,606 cells. The Y chromosome con-
tains 64 protein coding genes: 45 in the male-specific region 
(MSY) and 19 in the pseudo-autosomal regions (PARs). We 
detected the normal expression of 20 protein coding genes 
on chromosome Y across all white blood cells (Supplemen-
tary Fig. 1), enabling the classification of single cells with 
or without LOY. We identified single cells with LOY in 
all 29 subjects studied with scRNAseq and observed that 
the distribution of LOY varied substantially between cell 
types (Supplementary Fig. 2). Specifically, the frequency of 
LOY in NK cells, monocytes, B- and T lymphocytes were 
27% (7–87%), 23% (7–87%), 7% (2–40%), and 3% (1–6%), 
respectively. We also performed bulk RNA sequencing 
(RNAseq) on 134 samples of sorted cell fractions (NK cells, 
monocytes and granulocytes) collected from 51 subjects, 
including the 29 subjects studied with scRNAseq (Supple-
mentary Fig. 2).
We observed a high concordance in LOY estimates gener-
ated from pairwise samples studied in vivo with scRNAseq, 
RNAseq, and DNA based technologies (Supplementary 
Fig. 3). Furthermore, we studied in vitro changes of gene 
expression using RNAseq in 13 lymphoblastoid cell lines 
(LCLs) with or without LOY (Supplementary Figs. 4 and 5). 
Concordant levels of LOY were observed in LCLs studied 
with SNP-array as well as with a new method for LOY anal-
ysis [21] using droplet digital PCR targeting a 6-bp sequence 
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difference between the AMELY and AMELX genes (Pear-
son’s correlation coefficient = 0.9961; details not shown).
Many autosomal genes are dysregulated in LOY cells
To identify LOY Associated Transcriptional Effects (LATE), 
we tested for differential gene expression between the LOY 
and non-LOY cellular populations (Fig. 1, Table 1, Supple-
mentary Fig. 6, see “Materials and methods”). As expected, 
MSY gene expression was greatly decreased in the bulk 
RNAseq on sorted cells and absent in the single cell data (as 
this was the LOY definition for single cells). A correspond-
ing analysis of the genes located in the PARs also showed 
a decrease in transcript abundance with increasing levels 
of LOY. However, the decrease in PAR genes was not as 
distinct as for the MSY genes, which was expected because 
of sustained expression of the chromosome X-copy (Fig. 1, 
Supplementary Fig. 4).
Outside of the Y chromosome, we found evidence for 
489 autosomal LATE genes and 10 on the non-PAR X 
chromosome across the two expression datasets and all 
types of leukocytes, from in vivo studied samples (Fig. 1, 
Table 1, Supplementary Table 1). Of these, 75 were iden-
tified in the single cell data and 420 in the bulk RNAseq 
and we observed overexpression as well as underexpres-
sion of specific autosomal LATE genes. The autoso-
mal genes showing the largest LATE were LYPD2 and 
IL1R2, displaying 8.6 higher (DE = 3.11, FDR = 0.0011) 
and 2.5 lower (DE = − 1.30, FDR = 0.0612) abundance 
of transcripts, respectively. A considerable number of 
genes were independently identified as showing LATE 
in different cell types and by both technologies (Sup-
plementary Table  2). Co-expression analysis showed 
that autosomal genes that are normally co-expressed 
with MSY genes displayed a higher level of differen-
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NK cells (β = -5.3e-4, p = 0.43)
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Gran. (β = 6.2e-4, p = 0.0120)  
Mono. (β = 8.6e-4, p = 0.0004) 
NK cells (β = 2.4e-3, p = 0.0110)
Fig. 1  LOY associated transcriptional effect (LATE) in leukocytes 
in  vivo. On the X-axes are the level of LOY mosaicism (estimated 
from DNA by SNP-array from three sorted cell populations) and on 
the Y-axes are the normalized level of gene expression estimated from 
the same samples using RNAseq. Panel a display the average expres-
sion of six genes located in the male-specific part of chromosome Y 
(MSY) as a function of LOY. Panel b shows corresponding analysis 
of 13 genes located in the pseudo-autosomal regions of chromosomes 
X and Y (PAR). Panels c, d illustrate the finding of autosomal LATE 
genes, i.e., genes located on other chromosomes showing reduced or 
increased abundance of transcripts in samples with LOY. Panel c dis-
plays the average expression of the ten most underexpressed autoso-
mal LATE genes and the ten most over-expressed autosomal LATE 
genes is shown in panel d. Grey areas represent the standard error of 
linear regression models and beta (β) with confidence estimate (p) is 
shown. Mono. monocytes, Gran. granulocytes
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control genes (Supplementary Fig. 4, Wilcoxon rank sum 
test: p = 0.0021, see “Materials and methods”). Results 
from in vitro studied LCL’s further support that LOY is 
associated with altered autosomal gene expression using 
a complementary approach (Supplementary Figs. S4 and 
S5, Kolmogorov–Smirnov test: D = 1.0, p = 0.0016).
In the monocytes and NK cells that were studied by 
two RNA sequencing methods, the identified LATE genes 
showed an overall concordance in the direction of change 
in gene expression between technologies (binomial sign 
test; monocytes: p = 0.030, NK cells: p = 0.001). The level 
and direction of differential expression of LATE genes 
detected independently by both technologies are illus-
trated in Fig. 2. Among these, two genes were detected 
in both cell types and by both methods, i.e., upregulation 
of the LY6E gene located on chromosome 8 and down-
regulation of the PAR gene CD99.
Furthermore, we observed that the fraction of LATE 
genes within specific cell types was substantially larger 
than the fraction of LATE genes shared between different 
subsets of cells, in both the RNAseq dataset (ANOVA: 
F1,8 = 95.5, p < 0.0001) and in the scRNAseq dataset 
(ANOVA: F1,8 = 13.7, p = 0.0061). For instance, up to 
15% of normally expressed genes showed LATE in NK 
cells, but only about 2% of LATE genes were shared 
between NK cells and granulocytes or monocytes (Sup-
plementary Fig. 7). This result emphasizes that transcrip-
tomic alterations associated with LOY vary between dif-
ferent types of immune cells, likely because each cell 
type normally express a set of genes that is only partially 
overlapping with the gene expression of other cell types.
Biological pathways implicated by identified LATE 
genes
The 489 autosomal LATE genes had twice as many 
(p < 1 ×  10–16) biological connections amongst each other 
than expected by chance for a matched randomly selected 
set of genes. Furthermore, LATE genes were not randomly 
distributed throughout the genome, with clusters of genes 
evident (Supplementary Fig. 8). This was most pronounced 
in the 11q13.1 region, where we identified 17 LATE genes 
(13 over-expressed in LOY) in an 8 Mb genomic window 
(Supplementary Table 1). To explore the potential biological 
relevance of the identified genes, we next performed path-
way enrichment analyses, controlling for the background set 
of all genes expressed in our tested cell types. This resulted 
in the identification of a large amount of significantly over-
represented (FDR < 0.05) GO categories and pathways, the 
majority of which focused on aspects of RNA processing, 
immune function and the viral life cycle. Specifically, 191 
pathways and GO categories was identified using the DAVID 
functional annotation tools and 104 was identified using the 
Panther classification system (Supplementary Table 3). A 
summary of our literature review for detected LATE genes 
is presented in Supplementary Table 4.
We next tested whether LATE genes were preferentially 
located near genetic variants associated with LOY [4]. Gene 
set enrichment analysis implemented in MAGENTA dem-
onstrated a modest excess of such associations (1.17 fold 
enrichment, p = 0.010), with 41 LATE genes mapping within 
300 kb of a genome-wide significant SNP association in 25 
genomic regions. In several instances, the proximal LATE 
Table 1  Number of autosomal genes showing LATE in samples studied by two independent RNA sequencing methods
Number of autosomal LATE genes detected in vivo by RNAseq and/or  scRNAseq# = 489
* Results from RNAseq and scRNAseq analyses are shown separately for each cell type. The detected number (N.) of expressed genes as well as 
the number of LATE genes detected in different cell types using FDR < 0.1 are shown
# The number of unique genes after exclusion of overlaps between cell types and/or methods
Cell type Results from RNAseq  analysis* Results from scRNAseq  analysis*
N. of expressed genes in sam-
ples without LOY
N. of LATE genes in sam-
ples with LOY
N. of expressed genes in nor-
mal non-LOY cells
N. of LATE genes 
in single cells with 
LOY
NK cells 9974 298 3021 37
Monocytes 9891 80 3634 28
Granulocytes 7497 57 – –
T lymphocytes – – 2798 13
B lymphocytes – – 3112 3
LCL’s 9549 757 – –
Number of  genes# 11,472 1155 4631 75
Number of LATE genes in vivo# 420 75
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gene was the same as that prioritized through gene map-
ping approaches in the GWAS study. For example, LATE 
gene cyclin-dependent kinase inhibitor 1C (CDKN1C) was 
linked via expression changes to a nearby LOY-associated 
variant (rs60808706). Here, the LOY risk increasing allele 
increases expression of CDKN1C and the expression of 
CDKN1C is increased in cells with LOY. As with our previ-
ously reported example of TCL1A [4], this observation raises 
the possibility of a bi-directional relationship between LOY 
and CDKN1C—genetically increased expression of the gene 
promotes LOY and LOY subsequently further dysregulates 
gene expression in a cell-specific manner, possibly leading 
to a negative spiral of increased clonal mosaicism via per-
turbed cell-cycle processes.
LOY in sorted leukocytes from patients 
with prostate cancer and Alzheimer’s disease
Finally, we investigated the distribution of LOY in six types 
of sorted leukocytes—CD19 + B lymphocytes, CD4 + T 
lymphocytes, CD8 + T-cytotoxic lymphocytes, Natural 
Killer (NK) cells, granulocytes, and monocytes—among 
men diagnosed with Alzheimer’s disease (N = 121) or pros-
tate cancer (N = 107) vs. healthy controls (N = 156). Overall, 
there was a general trend for LOY to be increased in patients 
vs. controls, and this rate varied considerably between cell 
types (Fig. 3). Men with Alzheimer’s disease had signifi-
cantly higher levels of LOY only in CD16 + /CD56 + NK 
cells compared to controls (p = 0.0071). The fraction of 
Alzheimer’s disease cases with high levels of LOY in NK 
cells was about four times larger compared with controls and 
supports previous observations that LOY is associated with 
incident Alzheimer’s disease [9]. Furthermore, the involve-
ment of NK cells in the pathogenesis of Alzheimer’s disease 
has been suggested before in a range of experimental study 
designs [31–39]. In prostate cancer patients, NK cells did not 
show significantly higher level of LOY compared with con-
trols. However, in the latter cohort, the CD4 + lymphocytes 
and granulocytes were more frequently affected by LOY 
(p = 0.033 and p = 0.031, respectively). Although not prov-
ing direct evidence of causality, the observation that pros-
tate cancer and Alzheimer’s disease patients were primarily 
Fig. 2  Differential expres-
sion (DE) of specific genes as 
an effect of LOY in NK cells 
and monocytes, studied by 
both RNAseq and scRNAseq. 
Panels a, b illustrate the level 
of DE in 206 and 60 autosomal 
LATE genes identified in each 
cell type after correction for 
multiple testing (FDR < 0.1) 
and with at least an average of 
100 reads per gene in samples 
without LOY. Names are shown 
for LATE genes known to be 
linked with immune system 
functions and/or cancer and/
or development of Alzheimer’s 
disease. Panels c, d display DE 
observed in autosomal and PAR 
genes that was identified as 
LATE genes by both RNAseq 
and scRNAseq at a 0.05 α-level. 
MSY genes were excluded 
because of lack of expression 
in cells without chromosome 
Y. Independent identification 
of LATE was observed for 16 
and 7 genes in the NK cells 
and monocytes, respectively. 
The autosomal gene LY6E and 
the PAR gene CD99 displayed 
LATE in both cell types and by 
both technologies


































DE in single cells with LOY (scRNAseq)
-0.2 0 0.2-0.4 0.4
-1.0 -0.5 0 0.5
DE in samples with LOY (RNAseq)
1.0
LATE genes in monocytes identified by
both RNAseq and scRNAseq
-1.0 -0.5 0 0.5
DE in samples with LOY (RNAseq)
1.0
DE in single cells with LOY (scRNAseq)
-0.2 0 0.2-0.4 0.4
LATE genes in NK cells identified by




































































 J. P. Dumanski et al.
1 3
affected with LOY in different types of immune cells would 
support a disease-specific link. This suggests that associa-
tions between LOY and disease cannot solely be attributed to 
a confounding age-dependent process of genomic instability, 
which would be expected to equally affect different types 
of leukocytes. Our results are thus compatible with both 
hypotheses presented in the introduction regarding aetiology 
of LOY and disease; accumulation of LOY in leukocytes as 
a barometer of genomic instability in somatic cells, as well 
as increasing risk for different types of disease when specific 
types of immune cells are affected with LOY.
Discussion
Our study shows associations between LOY and dysregula-
tion of autosomal gene expression in leukocytes, provid-
ing two major insights. First, it highlights a surprisingly 
broad molecular role for the Y chromosome, which is often 
considered a “genetic wasteland” with limited involvement 
in the aetiology of complex traits and diseases. The expres-
sion of SRY on the Y chromosome is required in mammals 
to override the development of the default female sex. The 
mammalian sex chromosomes evolved from a pair of auto-
somes over the past 300 million years and the Y chromo-
some has been remarkably stable over the past 25 million 
years [40, 41]. Characterization of human chromosome Y 
has, however, been limited by the challenges of sequenc-
ing the highly repetitive regions as well as assaying its 
sequence variation for testing in large population studies. 
Mosaic loss of chromosome Y in hematopoietic cells was 
long considered as a neutral event. However, this view has 
been challenged by recent epidemiological studies describ-
ing associations between LOY in blood cells and increased 
risk for various disease [6–15]. Furthermore, results from 
serially studied subjects found an association between LOY 
and clonal expansions in peripheral blood, with the fre-
quency of LOY typically increasing in frequency over time 
CD19+ B lymphocytes 
CD4+ T lymphocytes 












Logistic regression adjusted for age and
smoking comparing level of LOY (%) in different




















































CD19+ B lymphocytes 
CD4+ T lymphocytes 











Logistic regression adjusted for age and
smoking comparing level of LOY (%) in different
types of leukocytes in PC patients vs. controls 
d

































































Fig. 3  Distribution of LOY in six populations of leukocytes in men 
diagnosed with Alzheimer’s disease or prostate cancer vs. controls. 
Leukocytes were sorted by FACS, followed by SNP-array genotyping 
for each cell fraction and calculation of the percentage of LOY. The 
numbers in parentheses under the X-axes in panels a, b denote the 
number of studied subjects for each cell type. Panels a, b show results 
from unadjusted analyses and panels c and d show results from logis-
tic regression models adjusted for age and smoking. Ctrl. control, AD 
Alzheimer’s disease, PC prostate cancer, LR logistic regression, OR 
odds ratio, lymph. Lymphocytes, NK natural killer
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in aging men [21]. However, some subjects showed other 
longitudinal patterns, suggesting that mechanisms such as 
age-related cellular senescence might be associated with 
recovery from LOY over time. Moreover, the co-occurrence 
of LOY and somatic mutations in genes linked with clonal 
hematopoiesis of indeterminate potential (CHIP) has been 
described in bone marrow samples from patients diagnosed 
with hematological malignancies [42]. Hence, the observed 
clonal expansion of LOY in peripheral blood might be 
related to such co-existence of LOY and CHIP mutations 
in progenitor cells and further studies are needed to under-
stand their relative contribution and implications for clonal 
hematopoiesis and disease risk. Furthermore, two recent 
papers further highlight the importance of normal expres-
sion of chromosome Y genes in the context of risk for cancer 
and Alzheimer’s disease in men. By estimating the extreme 
down-regulation of chromosome Y (EDY) using transcrip-
tomic data from 19 studies, it was found that EDY in blood 
cells was clearly associated with cancer risk (OR = 3.66) as 
well as greater EDY in tumor samples compared with nor-
mal tissue (OR = 8.33) [43]. A similar study that performed 
EDY analyses of transcriptomic data from five Alzheimer’s 
disease case–control studies found that the normal expres-
sion of chromosome Y genes (i.e., avoidance of EDY) in the 
brain could be associated with protection from developing 
this disease in aging men [44]. The results reported here, 
indicating that LOY is associated with dysregulated expres-
sion of ~ 500 autosomal genes, further support the notion 
that this chromosome may have a broader relevance in regu-
lation of the transcriptome and associated risk for disease, 
than is currently appreciated.
Furthermore, we describe here associations indicating 
that patients with Alzheimer’s disease might primarily be 
affected with LOY in NK cells, while men diagnosed with 
prostate cancer appears to more frequently display LOY in 
CD4 + T cells and granulocytes. These observations suggest 
a cellular specificity of LOY that would support a disease-
specific link, which needs to be replicated in additional 
cohorts. A cellular specificity of LOY with increased risk 
for different types of disease, together with the observation 
that the fraction of LATE genes within specific cell types 
was substantially larger than the fraction of LATE genes 
shared between different subsets of leukocytes (Supple-
mentary Fig. 7), suggests that LOY might have pleiotropic 
effects. Pleiotropy is defined as an effect of one feature at 
the genetic level to multiple characteristics at the phenotypic 
level [45]. Considering the large number of epidemiologi-
cal associations between LOY in blood and various disease 
outcomes, the LOY-pleiotropy might be a plausible concept. 
Our results are also in agreement with three experimental 
studies in mice, which support the potential cell type specific 
effects that Y chromosome may have on leukocyte popula-
tions and disease [46–49].
Second, our study highlights altered immune cell function 
that could conceivably link LOY in immune cells directly 
to disease mechanism(s). The combined number of LATE 
genes derived from analyses of various cells is surprisingly 
large, which suggests that a loss of ~ 2% of the male hap-
loid genome (via LOY) could have an impact on cellular 
homeostasis. Enrichment analyses showed that LATE genes 
are important for a range of physiological functions (Sup-
plementary Table 3) including many normal functions of 
the immune system. One of the LATE genes that showed 
the strongest downregulation was the autosomal gene LAG3 
(Fig. 2). The LAG3 protein is a cell surface molecule that 
functions as an immune checkpoint receptor by binding its 
main ligand MHC class II with higher affinity than CD4. 
Cellular proliferation and immune cell activation is regulated 
by a balance between CD4/LAG3, in a similar fashion to the 
CTLA4 and PD1 immune checkpoints, where LAG3 expres-
sion suppresses cell activity [50, 51]. The observed low 
expression of LAG3 in LOY cells might disrupt the CD4/
LAG3 balance by releasing one of the breaks of immune 
cell activity. Furthermore, it is noteworthy that the immune 
checkpoint PD-1 signaling pathway is one of the top hits in 
the enrichment analysis (Supplementary Table 3).
Furthermore, the genes LY6E and CD99 showed LATE 
by both RNAseq and scRNAseq in NK cells and monocytes 
(Fig. 2). The protein product of CD99 is a cell surface gly-
coprotein involved in processes such as leukocyte migration, 
cell adhesion and apoptosis; e.g., by functioning as a diape-
desis-mediating receptor central for migration of monocytes 
through endothelial junctions [52, 53]. A lower expression 
of CD99 in leukocytes with LOY might, therefore, mitigate 
extravasation and thus impair the recruitment and move-
ment of leukocytes from circulation towards somatic tis-
sues and sites of disease. Furthermore, the LY6E gene was 
upregulated as an effect of LOY and it has the potential to 
inhibit inflammatory cytokines and disrupt inflammatory 
cascades. A survey of more than 130 published clinical 
studies found that increased expression of LY6E is associ-
ated with poor survival outcome in multiple malignancies 
[54] and it has also been found to be important for drug 
resistance and tumor immune escape in breast cancer [55]. 
Among all autosomal LATE genes, the IL1R2 gene showed 
the strongest downregulation in immune cells with LOY. 
This cytokine receptor is central for orchestrating inflam-
matory and immune responses by binding of ligands such 
as interleukin-1α (IL1A), interleukin-1β (IL1B), and inter-
leukin 1 receptor antagonist (IL1Ra), preventing them from 
binding to other receptors [56]. Hence, a lower abundance 
of IL1R2 in LOY cells could reduce the inhibiting effect of 
this receptor.
Additionally, several of the LATE genes we identified 
had diverse and well-described roles in other biological 
processes, notably GABRR1, PRLR, and LEP. GABRR1 
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encodes a receptor for Gamma Aminobutyric Acid (GABA), 
the major inhibitory neurotransmitter in the brain. A recent 
study found these receptors were functionally expressed 
in human and mouse hematopoietic stem cells and mega-
karyocyte progenitors [57]. Overexpression of GABRR1 
in these cells led to increased rates of megakaryocyte and 
platelet differentiation. In contrast, we observed 1.26-fold 
(p = 7.9 ×  10–5) increased expression of the receptor in NK 
cells lacking the Y chromosome, extending the biological 
role of this receptor in immune cell function. Sex hormone 
receptors have also been described to have functional effects 
on hematopoietic stem/progenitor cells [58] including the 
prolactin receptor (PRLR), which we see over-expressed in 
monocytes with LOY (Supplementary Table 2). We also 
observed over-expression of the hunger inhibiting hormone 
Leptin (LEP) in granulocytes with LOY, consistent with 
studies describing its lesser known roles in regulating innate 
immune response [59].
Conclusions
As mentioned in the introduction, LOY is the most com-
mon post-zygotic mutation from analyses of bulk DNA from 
peripheral blood. The current study adds new information on 
this as all 29 men (median age 80 years, 64–94 years) stud-
ied by scRNAseq carried leukocytes without chromosome Y. 
Thus, LOY is more common than so far appreciated and the 
future analyses of single- or sorted-cells from various tissues 
will be instrumental for establishment of true frequency of 
this mutation as well as for identification of cell subtypes 
most often associated with disease. Lastly, we describe that 
LOY is associated with dysregulation of ~ 500 autosomal 
genes, for example, involved in immune functions but also 
with roles in other biological processes. The present study 
provide insights into the molecular role of the Y chromo-
some and bring forth clues on how its mosaic loss in leu-
kocytes could be associated with increased risk for disease 
in affected men, which ought to stimulate further research.
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